Structure Therapeutics published Phase 2 results showing its oral GLP‑1 agonist aleniglipron achieved roughly 16% mean weight loss versus placebo at 44 weeks, positioning the company to escalate toward Phase 3, multiple reports said. The topline places aleniglipron ahead of other oral GLP‑1 candidates reported to date and intensifies competition with injectable incumbents from Eli Lilly and Novo Nordisk. Regulators will weigh durability and safety endpoints in any accelerated development path; investors and competitors will track manufacturing scale and oral bioavailability data as the program advances.